IPD — ImpediMed Income Statement
0.000.00%
Last trade - 00:00- AU$14.64m
- AU$15.95m
- AU$14.61m
Annual income statement for ImpediMed, fiscal year end - June 30th, AUD millions except per share, conversion factor applied.
2022 June 30th | 2023 June 30th | 2024 June 30th | 2025 June 30th | 2026 June 30th | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 10.6 | 11.3 | 10.3 | 12.7 | 14.6 |
| Cost of Revenue | |||||
| Gross Profit | 8.86 | 9.8 | 9.01 | 11 | 12.8 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Depreciation and Amortization | |||||
| Operating Interest Expense / Income | |||||
| Unusual Expense / Income | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 30.4 | 31.8 | 30.1 | 35.9 | 39.5 |
| Operating Profit | -19.8 | -20.5 | -19.8 | -23.2 | -24.9 |
| Net Income Before Taxes | -19.8 | -20.5 | -19.8 | -23.2 | -24.9 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -19.9 | -20.5 | -19.8 | -23.2 | -24.9 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -19.9 | -20.5 | -19.8 | -23.2 | -24.9 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -19.9 | -20.5 | -19.8 | -23.2 | -24.9 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.012 | -0.011 | -0.01 | -0.012 | -0.012 |